Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UPLIFT reassures some over Spiriva CV safety

This article was originally published in Scrip

Executive Summary

Boehringer Ingelheim/Pfizer's leading COPD treatment Spiriva (tiotropium bromide) failed to reduce the rate of decline in FEV1 over four years of treatment, the results of the large, long-term UPLIFT study show, but the researchers have found positive effects from the drug and the data have provided some reassurance over the its cardiovascular safety, the subject of great scrutiny in recent weeks.

You may also be interested in...



GSK’s Dostarlimab Gets EU Nod For Endometrial Cancer

While its NDA languishes at the US Food and Drug Administration, the EMA’s CHMP has said yes to dostarlimab’s marketing in the EU for endometrial cancer.

COVID-19 Promise Fulfilled, But Where Next For mRNA Vaccines?

After a baptism of fire during the coronavirus pandemic, mRNA vaccine technology has earned its stripes. In less than a year, mRNA vaccines have been catapulted from interesting pipeline prospects to game-changers in the fight against COVID-19. But what does this success mean for the future of the technology?

AstraZeneca’s Imfinzi Fails Again In Head And Neck Cancer

The Phase III KESTREL study evaluating Imfinzi missed its primary overall survival benefit and a key secondary outcome in first-line recurrent or metastatic head and neck squamous cell carcinoma.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel